Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tipranavir/Ritonavir QT Interval Study
NCT02248883Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2005
- Primary completion
- Mar 2006
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of tipranavir in human immunodeficiency virus infection (HIV) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Change from baseline in individually heart rate corrected QT interval length (QTcI). Started Dec 2005; status: completed.
02
Drugs
tipranavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02248883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02248883.